Key takeaways

  • Largest mean weight reduction observed for any approved compound in its class — up to 20.9% over 72 weeks at the 15mg dose.
  • Dual GIP + GLP-1 agonism appears to outperform single GLP-1 agonism on body composition outcomes.
  • Strong evidence base: 5 published phase-3 RCTs, n > 11,000 across SURMOUNT and SURPASS programs.
  • Common GI side effects (nausea, constipation) usually resolve with slow titration.
  • UK: prescription-only. Approved for type-2 diabetes (Mounjaro) and chronic weight management; not legal for non-prescribed use.

What it is

Tirzepatide is a 39-amino-acid synthetic peptide that activates two incretin receptors simultaneously: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). It was developed by Eli Lilly and approved by the US FDA in May 2022 for type-2 diabetes (Mounjaro), and in November 2023 for chronic weight management (Zepbound). UK MHRA approval followed in October 2023.

Structurally it's modified from native GIP, with a fatty-acid moiety that binds reversibly to albumin — extending its half-life to roughly 5 days and enabling once-weekly subcutaneous dosing.

How it works

Both GIP and GLP-1 are incretin hormones — released by the gut in response to nutrient intake. They potentiate insulin secretion, suppress glucagon, and slow gastric emptying. Tirzepatide's distinguishing feature is co-activation of both pathways from a single molecule.

Step 1
Subcutaneous injection

Weekly dose absorbed into circulation; albumin-bound for slow release.

Step 2
Receptor binding

Activates GIP and GLP-1 receptors in pancreas, gut, and brain.

Step 3
Insulin response

Glucose-dependent insulin release; glucagon suppressed.

Step 4
Appetite & satiety

Slowed gastric emptying; central satiety signalling increases.

The clinical effect — pronounced reduction in caloric intake, improved insulin sensitivity, and significant fat-mass loss — appears to compound across these mechanisms rather than coming from any single pathway.

Benefits

Weight reduction (high confidence)

The SURMOUNT-1 trial (n=2,539, 72 weeks) reported mean body-weight reductions of −15.0%, −19.5%, and −20.9% at 5mg, 10mg, and 15mg respectively, vs −3.1% on placebo. These are the largest reductions observed for any pharmacologic agent in this class to date.

Glycaemic control (high confidence)

In type-2 diabetics (SURPASS-2), tirzepatide outperformed semaglutide on HbA1c reduction at every dose level. Mean HbA1c reductions reached −2.30% at the 15mg dose.

Cardiovascular outcomes (medium confidence)

Pre-specified meta-analyses suggest reductions in MACE risk; the dedicated SURPASS-CVOT trial is ongoing as of early 2026. Definitive cardiovascular conclusions await its publication.

Where the evidence is thinner
Long-term (>3 year) data is still accumulating. Effects on lean-mass preservation are favourable but trial-design limitations make this a developing rather than settled question. Discontinuation typically results in significant weight regain.

Research summary

Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)
2022
Phase-3 RCT, double-blind, placebo-controlled·n = 2,539

At 72 weeks, mean weight reduction was −20.9% on 15mg vs −3.1% on placebo. 91% of participants on the 15mg dose achieved ≥5% weight reduction.

N Engl J Med · doi:10.1056/NEJMoa2206038
Tirzepatide vs Semaglutide once weekly in patients with type-2 diabetes (SURPASS-2)
2021
Phase-3 RCT, open-label, head-to-head·n = 1,879

Tirzepatide demonstrated greater HbA1c and weight reduction than semaglutide 1mg at all three doses studied. Side-effect profile broadly comparable.

N Engl J Med · doi:10.1056/NEJMoa2107519
Effects of tirzepatide on cardiovascular outcomes (SURPASS-CVOT)
Ongoing
Phase-3 RCT, primary CV outcomes·n = 13,299

Pre-specified MACE-3 endpoint analysis underway. Interim safety data consistent with prior trials. Primary readout expected 2026–2027.

ClinicalTrials.gov · NCT04255433

Dosage & administration

Tirzepatide is administered as a weekly subcutaneous injection. Dose escalation is critical to tolerance — abrupt initiation at higher doses produces near-universal GI symptoms.

PhaseDoseDurationNotes
Initiation2.5 mg / week4 weeksTolerance phase only
Step 15.0 mg / week4+ weeksLowest therapeutic dose
Step 27.5 mg / week4+ weeksOptional intermediate
Step 310.0 mg / week4+ weeksCommon maintenance
Maximum15.0 mg / week—Highest approved dose
Standard titration schedule per UK SmPC. Always escalate under clinical supervision.
Educational summary, not a prescription
Dosing data is summarised from published clinical-trial protocols and the UK Summary of Product Characteristics. It is provided for educational reference only. Specific dose decisions must be made by a UK-registered prescriber familiar with your medical history.

Side effects & safety

The side-effect profile is dominated by GI symptoms, particularly during titration. Most are dose-dependent and transient.

EffectFrequencySeverity
Nausea30–40%Mild–moderate
Diarrhoea15–22%Mild
Constipation10–18%Mild
Vomiting9–13%Mild–moderate
Injection-site reaction3–5%Mild
Acute pancreatitis<0.5%Serious — discontinue

Contraindications: Personal/family history of medullary thyroid carcinoma or MEN-2. Use during pregnancy is not recommended.

Prescription-only medicine (POM) in the UK
Tirzepatide is licensed in the UK under the brand names Mounjaro (type-2 diabetes) and as a chronic weight-management therapy. Supply outside a prescription is illegal under the Human Medicines Regulations 2012. The MHRA has issued multiple warnings about counterfeit injector pens sold via unregulated channels — these have included incorrect dosing, unsterile preparations, and entirely different active ingredients.

Summary

Tirzepatide currently sits at the front of the evidence base for pharmacologic weight management, with effect sizes that exceed any prior agent. The dual-incretin mechanism appears genuinely additive rather than just incremental over GLP-1-only therapy. For UK readers: it's available on prescription, including via private clinics; supply outside that route is both illegal and demonstrably unsafe given the counterfeit market. Discontinuation produces significant rebound — long-term planning matters.

References (12)
  1. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
  2. Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Mol Metab. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009
  3. Frías JP, et al. Tirzepatide versus Semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519
  4. Sattar N, et al. Tirzepatide cardiovascular event risk assessment: pre-specified meta-analysis. Nat Med. 2022;28(3):591-598. doi:10.1038/s41591-022-01707-4
  5. Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626.
  6. Wadden TA, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). Nat Med. 2023;29(11):2909-2918.
  7. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024;331(1):38-48.
  8. MHRA. Mounjaro 2.5/5/7.5/10/12.5/15 mg solution for injection — Summary of Product Characteristics. October 2023.
  9. NICE. Tirzepatide for managing overweight and obesity. Technology appraisal guidance TA1026. December 2024.
  10. Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide (SURPASS-1). Lancet. 2021;398(10295):143-155.
  11. Inagaki N, et al. SURPASS-J-mono: tirzepatide monotherapy in Japanese adults with type 2 diabetes. Lancet Diabetes Endocrinol. 2022;10(9):623-633.
  12. MHRA Drug Safety Update. Counterfeit Mounjaro injector pens: clinician alert. January 2025.
This page has been peer-reviewed by a clinician. How we review content →